Hence, the introduction of the recombinant humanized monoclonal antibody anti-VEGF (vascular endothelial growth factor), bevacizumab, approved in 2009 in the United States as an anti-angiogenic adjuvant therapeutic strategy for recurrent GBM, raised initial enthusiasm among clinicians, but unfortunately, it was rapidly attenuated due to its limited survival advantage compared with experimental therapy at recurrence [6]. This evidence concerns the gene VEGFA and glioblastoma.